anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This invention involves the establishment of manufacture of clinically useful controlled release parenteral formulation of buprenorphine hydrochloride/buprenorphine base microparticle delivery system. Buprenorphine and buprenorphine hydrochloride has been used for the treatment of pain and drug addiction. In view of minimizing the frequency of dosing and avoiding surgical procedures, controlled release parenteral dosage forms are developed using biocompatible and biodegradable polymers. These parenteral formulations also avoid oral absorption problems and potential abuse associated with other possible forms of administration such as sublingual, nasal and transdermal dosage forms. Poly-(lactic acid), poly-(glycolic acid) and their copolymers and mixture of these polymers are used for the development of microencapsulation of a buprenorphine and buprenorphine hydrochloride by solvent evaporation from oil/water emulsion. In the body, polymers are known to degrade to lactic and hydroxy-acetic acids, which are readily metabolized and eliminated.
The present invention relates to a medicinal preparation for curing viral and many kinds of myocarditis, low fever and hypopotassemia. The medicinal preparation is prepared by matching Chinese medicinal materials with the functions of resolving the exterior, clearing heat, enriching yin, supplementing blood, nourishing the heart, quieting spirit and supplementing qi and/or extracts thereof. The dosage form is oral liquor, a capsule or powder. In 1973 treated cases, the clinical cure rate is 93.41%. The curative effect of the medicinal preparation is better than that of a control group in which patients are treated by conventional western medicine by 54.36%. The present invention also provides the necessity of applying the two-ways regulation functions of traditional Chinese medicine and regulating electrolyte balance besides regulating immunity, particularly maintaining potassemia at a high physiological level of 4.4 to 4.8 mmol/L when myocarditis is treated, what is one of keys for improving the clinical symptoms of patients and curing the patients.
Patients receive BRD4 inhibitor PLX51107 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The present invention relates to system and method for production of DNA particles and use thereof. The DNA particles can be produced by amplification of nucleic acid molecule(s). Alternatively, DNA particles can be prepared by condensing multiple DNA molecules. The DNA condensation into a particle is mainly triggered by pyrophosphate and positively charged cations (e.g. magnesium). DNA particles can be applied for numerous biological applications but not limited to directed evolution, proteomics, drug delivery and imaging. DNA particles can be used to synthesize proteins using in vitro transcription/translation reaction.
FIELD: food industry. ^ SUBSTANCE: invention concerns chemical pharmaceutical and food industry and refers to yeast containing product, which can be used in medicine and dietary and sport feeding. Preparation contains brewing and baking yeast and also yeast that is used in biotechnology and confectionary industry. The yeast is treated before its concentration and/or lysis, and or drying by plant extractions, which contain flavonoids or synthetic or natural antioxidants. ^ EFFECT: treatment of yeast by plant extractions which contain flavonoids or antioxidants provides increasing of its biological activity and is used for creation of products which increase efficiency, adaptability to extreme conditions of humans and animals. ^ 5 cl, 3 tbl, 3 ex
PCT No. PCT/US93/01135 Sec. 371 Date Oct. 5, 1993 Sec. 102(e) Date Oct. 5, 1993 PCT Filed Feb. 9, 1993 PCT Pub. No. WO93/16107 PCT Pub. Date Aug. 19, 1993.This invention provides a novel improved alpha interferon composition characterized by high specific activity, a purity of greater than 95% and which upon use in humans is further characterized by a substantial reduction in side effects normally associated with alpha interferon compositions. Also provided is a method for large scale production of the composition from human peripheral blood leukocytes. This alpha interferon composition may be used therapeutically in the treatment of cancers and diseases of the immune system and/or viral etiology.
AIMS: To confirm whether the pathological response of lymph node metastasis (LNM) to neoadjuvant chemotherapy (NCT) can predict the prognosis of patients with gastric cancer (GC).
METHODS: A total of 979 patients with locally advanced GC were included. χ2 test was used to analyze the relationship between LNM TRG and clinicopathological factors. Cox proportional hazards model was used to analyze the relationship between LNM TRG, clinicopathological factors, and overall survival (OS).
RESULTS: A total of 21,162 lymph nodes were evaluated, with 237 patients (35.4%) in the response group and 433 patients (64.6%) in the non-response group. The non-responsive group was strongly associated with higher ypT, ypN, ypTNM, primary tumor (PT) TRG (all p < 0.001), positive cancer nodules (p = 0.001), and more distant LNM location (p < 0.001). Patients with the same PT TRG but different LNM TRG had different prognosis. There was no difference in OS between the responding and non-responding groups of LNM at location 2, 3, and M. YpN, tumor location, and LNM location were independent prognostic factors.
CONCLUSIONS: The combination of LNM TRG and PT TRG could better predict patient prognosis. Lymph node dissection should be routinely performed after NCT to provide the reference of radical resection.
NEW MATERIAL:The toxoid of Pseudomonas aeruginosa elastase having the following characteristics. Molecular weight, 23,300 (measured by SDS-polyacrylamide gel electrophoresis); isoelectric point 6.0pH (measured by electrophoresis using an acetate membrane); amino acid composition, shown in Table 1; color, colorless powder; antigen activity, active; enzymatic activity, none. USE:Antibody, antiserum, and vaccine for preventing the infection with Pseudomonas aeruginosa. PREPARATION:The elastase separated and purified from the extracellular product of Pseudomonas aeruginosa is treated with 1% formalin solution to reduce the enzymatic activity to 1-10%, preferably about 5% of the original level, and the synthetic peptide reagent of formula is added to the product to decrease the enzymatic activity to <=1/500 of the original level. The amount of the reagent is 1-1/100pts.wt. per 1pt. of the enzyme remaining in the product. The objective toxoid of Pseudomonas aeruginosa elastase can be prepared thereby.
PROBLEM TO BE SOLVED: To obtain a water-soluble silver complex that manifests a wide range of antibacterial and antifungal spectra, simultaneously is soluble in water and stable to light and useful as an active ingredient for antibacterial and antifungal compositions by coordinating specific ligands to silver ion. SOLUTION: This complex is prepared by coordinating (A) 2-pyrrolidone-5- carboxylic acid or (B) histidine to (C) silver ion. This complex is obtained by allowing the component A or B to react with the component C at a suitable pH in an aqueous solution, then adding an organic solvent, for example, ethanol for fractional separation of the product. As a source of the component C, silver nitrate or silver oxide (I) can be used. In the case where the component B is used as ligand, however, the use of silver oxide is required. The complex can be formed by reaction of 1 mole of silver with 1-2 moles of components A or B, however, in the case of the component A, the equimolar amount of silver is preferably used, while the component B is preferably used by two moles per mole of silver.
OBJECTIVE: To describe the potential clinical cardiotoxicity of oncological treatments in a cohort of consecutive patients with hypertrophic cardiomyopathy (HCM), systematically followed-up at two national referral centers for HCM. Cardiotoxicity relates to the direct effects of cancer-related treatment on heart function, commonly presenting as left ventricular contractile dysfunction. However, limited data are available regarding cardiotoxic effects on HCM as most studies have not specifically analyzed the effects of oncological treatment in HCM populations. This gap in knowledge may lead to unjustified restriction of HCM patients from receiving curative cancer treatments.
METHODS: We retrospectively analyzed clinical and instrumental data of all consecutive HCM patients who underwent oncological treatment between January 2000 and December 2020 collected in a centralized database.
RESULTS: Of 3256 HCM patients, 121 (3.7%) had cancer; 110 (90.9%) underwent oncological surgery, 45 (37.2%) received chemotherapy, and 22 (18.2%) received chest radiation therapy (cRT). After a median follow-up of 5.2 years (Q1-Q3: 2-13 years) from oncological diagnosis, 32 patients died. The cumulative survival at 5 years was 79.9%. The cause of death was mainly attributed to the oncological condition, whereas four patients died of sudden cardiac death without receiving previous chemotherapy or cRT. No patient interrupted or reduced the dose of oncological treatment due to cardiac dysfunction. No sustained ventricular tachyarrhythmia was induced by chemotherapy or radiation therapy.
CONCLUSION: Cancer treatment was well tolerated in HCM patients. In our consecutive series, none died of cardiovascular complications induced by chemotherapy or cRT and they did not require interruption or substantial treatment tapering due to cardiovascular toxic effects. Although a multidisciplinary evaluation is necessary and regimens must be tailored individually, the diagnosis of HCM per se should not be considered a contraindication to receive optimal curative cancer treatment.
The present invention relates in a first aspect to a vaccine kit comprising a) a first vaccine component comprising i) a first set of one or more containers, each container containing a vaccine composition for intranasal administration, b) optionally a second vaccine component comprising a second set of one or more containers, each container containing a vaccine composition for intranasal administration, and c) optionally instructions for use, wherein each container of the first and second set of containers contains a volume of the vaccine composition from about 5 microliter to about 400 microliter. The present invention also relates to: An administration regimen for intranasal administration of a vaccine composition for use in immunizing a human. A device for use in administration of vaccine compositions. The use of: a) a first vaccine component comprising i) a first set of one or more containers, each container containing a vaccine composition for intranasal administration, b) optionally a second vaccine component comprising a second set of one or more containers, each container containing a vaccine composition for intranasal administration, wherein each container of the first and second set of containers contains a total volume of the vaccine composition from about 5 microliter to about 400 microliter for immunizing a human. The use of: a) a first vaccine component comprising i) a first set of one or more containers, each container containing a vaccine composition for intranasal administration, b) optionally a second vaccine component comprising a second set of one or more containers, each container containing a vaccine composition for intranasal administration, wherein each container of the first and second set of containers contains a total volume of the vaccine composition from about 5 microliter to about 400 microliter for the preparation of a vaccine for intranasally immunizing a human. The method of treating a person in need of a vaccination. The vaccine formulated for intranasal administering.
Subjects treated with Emervel Classic (moderate NLFs; WSRS = 3/3). Subjects receiving bilateral treatment of NLFs following approved product labeling.
INTRODUCTION: Pregnant women with pre-excitation syndrome are more likely to develop supraventricular tachycardia (SVT) during pregnancy and delivery, leading to an increased risk of adverse events.
METHOD: This was a retrospective study of 309 pregnancies in 280 women (29 women had two pregnancies in this series) with pre-excitation syndrome who delivered at West China Second University Hospital from June 2011 to October 2021. All the 309 pregnant women with pre-excitation syndrome were divided into SVT and non-SVT groups to analyze the cardiac and obstetric complications.
RESULTS: Among the included pregnant women in the past 10 years, the prevalence of pre-excitation syndrome was 0.24% (309/127725). There were 309 cases with pre-excitation syndrome in all hospitalized pregnant women. Among them, 62 (20.1%, 62/309) had a history of SVT. In the 62 cases with SVT during pregnancy, 22 (35.5%) cases had a history of SVT. Gestational diabetes mellitus was associated with SVT during pregnancy. The cesarean section rate was 88.7% in the SVT group, which was significantly higher than that in the non-SVT group (64.8%) (P < 0.001). Cases with SVT during pregnancy had more cardiac and obstetric complications. Four fetal deaths were recorded in the SVT group. Additionally, 29 women experienced two pregnancies during the study period, among whom, five received radiofrequency ablation after the first delivery and obtained better outcomes in the second pregnancy.
CONCLUSION: The adverse outcomes such as cardiac complications, maternal and fetal complications (PROM, prematurity, SGA, fetal distress, etc.) in pregnant women with pre-excitation syndrome were closely related to SVT, with possible risk factors including history of SVT before pregnancy, cardiac function, heart organic abnormalities, and gestational diabetes mellitus.
Acute overdosage with Cisplatin Injection may result in renal failure, hepatic failure, hearing loss, ocular toxicity, myelosuppression, nausea and vomiting, and neuritis. In addition, death can occur following overdosage.

Management of overdosage should include general supportive measures to sustain the patient through any period of toxicity that may occur. Important measures include renal protection by intravenous hydration with or without the use of an osmotic diuretic. Hemodialysis is not effective because of the high degree of protein binding of Cisplatin Injection. Plasmapheresis has been used to treat cases of Cisplatin Injection overdosage, but the optimal treatment regimen has not been established.

For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or www.poison.org.
A female infant presented to an Irish hospital with a 4-day history of fever, irritability and reduced oral intake. Initial inflammatory markers were significantly elevated, an erythematous tympanic membrane was noted on examination and an initial diagnosis of acute otitis media was made. By the third hospital day, the infant was noted to be irritable when being lifted up; pseudoparalysis of the right upper limb was observed. A radiograph of the right shoulder was normal; MRI identified acute scapular osteomyelitis with subperiosteal abscess formation. The child underwent 3 washout procedures and received 6 weeks of antibiotic therapy, with full clinical recovery at 3 months. This case highlights the importance of remaining flexible in the context of an evolving presentation and recognising hallmarks of musculoskeletal infection, fever, localised pain and pseudoparalysis. Additionally, we review the literature to highlight clues in diagnosis, treatment and outcome for paediatric acute scapular osteomyelitis.
The present invention relates to a compound traditional Chinese medicine preparation for treating bone fracture. The preparation uses a plurality of kinds of traditional Chinese medicine including notopterygium, angelica root, himalayan teasel, peony, cyathula root, bupleurum, safflower, peach seed, buck grass, speranskia herb, rhizoma homalonemae, dracorhodin, catechu, anomalin, etc. as raw materials, the raw materials are respectively processed or dried and are mixed proportionally after being ground, and the preparation is obtained after the raw materials are dried. The present invention can be applied externally and internally. The preparation has the efficacy of hemostasis, pain ease, rapid inflammation relieving, tissue regeneration and rapid bone recovery. The preparation has an obvious effect on treating bone fracture or osteoarthrosis, has the advantages of easy acquisition of raw materials and simple processing, and is suitable for industrialization production. The cure rate is 94.03% through the clinical verification of hundred thousand patients.
NEW MATERIAL:A compound shwon by the formula I (R<1>-R<3> are H, or CH3, and at least one is CH3; dotted line part is single bond or double bond) and its ester. EXAMPLE:2,5,7,8-Tetramethyl-2-(4,8,12,16-tetramethylheptadecyl)-6-chro manol. USE:An adjuvant. PREPARATION:A compound shown by the formula II (m is integer equal to number of CH3 linked to benzene ring of the desired compound) is condensed with a compound shwon by the formula III(X is OH, or halogen) or a compound shown by the formula IV in the presence of both an acid catalyst such as ZnCl2, H2SO4, etc. and metal powder such as Zn, Sn, etc. in a solvent such as benzene at 60-100 deg.C, to give a compound shown by the formula I wherein the dotted line part is a single bond.
In Part A, a single oral dose of placebo will be given. In Part C, placebo will be given twice daily for 7 days.
PURPOSE: An auto box management system is provided to assign unique identification information to an auto box, thereby easily managing the auto box. CONSTITUTION: A production management unit(10) generates an auto box. The production management unit authenticates whether or not the auto box is genuine by registering unique auto box identification information in an individual auto box. A hospital management unit(20) confirms whether or not the auto box is genuine by communication with the production management unit, and transmits information on medicine consumption to the production management unit. A cabinet(30) transmits the auto box identification information and medicine discharge situation information by communication with the hospital management unit. [Reference numerals] (10) Production management unit; (20) Hospital management unit; (30) Cabinet;
1. Viadur® is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components in Viadur®. Anaphylactic reactions to synthetic GnRH or GnRH agonist analogs have been reported in the literature.2
  2. Viadur® is contraindicated in women and in pediatric patients and was not studied in women or children. Moreover, leuprolide acetate can cause fetal harm when administered to a pregnant woman. Major fetal abnormalities were observed in rabbits but not in rats after administration of leuprolide acetate throughout gestation. There were increased fetal mortality and decreased fetal weights in rats and rabbits. The effects on fetal mortality are expected consequences of the alterations in hormonal levels brought about by this drug. The possibility exists that spontaneous abortion may occur.
The findings from the first 2 arms of the study will be used to inform a training-based study aimed to determine whether exercise together with this optimal dose of hydrolyzed collagen and vitamin C is sufficient to improve rate of force development (RFD) and performance. A gummy food will be developed with the optimized dose of hydrolyzed collagen and vitamin C as well as a placebo. In a randomized, double-blinded, parallel design with subjects undertake a 3 week exercise protocol. The supplement will be ingested 1 hour prior to each exercise session (Monday/Wednesday/Friday). Exercise testing to assess rate of force development (RFD) will take place at the end of each week (Fridays) and these outcomes will be the basis for determining the effects of the nutrition intervention on performance.
PURPOSE:To promote the anesthetic effect and elongate its duration, by adding a carboxylic acid salt or carboxylic acid ester having a specific hydrophobic group and optionally specific hydrophilic group, to a local anesthetic. CONSTITUTION:A carboxylic acid salt or a carboxylic acid ester having an aliphatic hydricarbon group or a benzene ring as a hydrophilic group and if necessary, a hydroxyl group or amino group as a hydrophilic group, is added to a local anesthetic (e.g. procaine hydrochloride). The carboxylic acid salt is, e.g. sodium acetate, sodium propionate, etc. as a chain carboxylic acid salt, and sodium benzoate, etc. as an aromatic carboxylic acid salt. The ester is, e.g. methyl ester. The duration of the anesthetic effect can be elongated by nearly 4-5 times by the addition of the carboxylic acid salt compared with the simple administratin of the local anesthetic. The anesthetic is useful for the mitigation of pain after operation, and for the operation requiring long time.
Interactions between astrocytes and microglia play an important role in the regeneration and repair of traumatic brain injury (TBI), and exosomes are involved in cell-cell interactions. A TBI model was constructed in rats. Brain extract (Ext) was isolated 1 d after TBI. Astrocyte-derived exosomes were obtained by coculturing Ext with primary astrocytes, and the morphology of exosomes was observed by electron microscopy. The isolated exosomes were cocultured with microglia to observe phenotypic changes in M1 and M2 markers. Aberrant RNA expression was detected in necrotic brain tissue and edematous brain tissue. The role of miR-148a-3p in regulating microglial phenotype was explored by knocking down or overexpressing miR-148a-3p. Finally, the effect of miR-148a-3p on TBI was studied in a rat TBI model. Astrocyte-derived exosomes stimulated by Ext promoted the transition of microglia from the M1 phenotype to the M2 phenotype. MiR-148a-3p was highly expressed in TBI. Transfecting miR-148a-3p promoted the transition of microglia from the M1 phenotype to the M2 phenotype and inhibited the lipopolysaccharide-induced inflammatory response in pre-microglia. In a rat TBI model, miR-148a-3p significantly improved the modified neurological severity score and attenuated brain injury, which promoted the transition of microglia from the M1 phenotype to the M2 phenotype. MiR-148a-3p alleviated TBI by inhibiting the nuclear factor κB pathway. Astrocyte-derived exosomal miR-148a-3p regulates the microglial phenotype, inhibits neuroinflammation, and restores neurological function in TBI. These results provide new potential targets for the treatment of TBI.
Itching is a prominent clinical manifestation of sensitive skin; it reduces cutaneous barrier function, mainly caused by dryness. Scratching to relieve itching destroys the skin barrier, thus forming the itch-scratch cycle that results in additional disruption of skin barrier and chronic itching. Treatment involves alleviation from itching for sensitive skin. Recently, substance P (11-amino acid neuropeptide of the tachykinin family) and neurokinin 1 receptor (NK1R) have been considered to provide a key pathway to treat chronic itching. A single-center, open-label study was conducted comprising subjects with dry, itchy, and sensitive skin to evaluate the efficacy of two types of itch-relief moisturizers, mist and lotion, containing maltotetraose (MTO). In all, 35 subjects used mist containing MTO, resulting in significant improvement in itch score from 1 minute to 2 hours following single application. On the other hand, 34 subjects applied lotion containing MTO for 1 week, resulting in significant improvement in itch score, skin hydration, and clinical scores of erythema/redness and dryness; however, in both cases, improve-ment was not observed in the measurement of transepidermal water loss (TEWL). It was concluded that two types of itch-relief moisturizers containing MTO were effective for dry, itchy, and sensitive skin.